---
document_datetime: 2025-10-15 18:36:05
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/duloxetine-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: duloxetine-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.8891531
conversion_datetime: 2025-12-24 21:21:03.15648
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Duloxetine Viatris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber   | Scope                       | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amended on   | Product Information affected3   | Summary   |
|---------------------|-----------------------------|-------------------------------------|-------------------------------------------|---------------------------------|-----------|
| Variation type IA / | A.ADMINISTRATIVECHANGES-A.7 | 10/10/2025                          |                                           | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                     | Deletionofmanufacturing sitesfor an active substance,intermediate or finished product, packaging site, manufacturer responsible for batchrelease,sitewherebatch control takes place,orsupplierofastartingmaterial, reagent orexcipient(when mentioned in the dossier)*- Accepted                                                                                                                                                                                                                         |            |     | PL   | EMA/VR/0000304267   |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|---------------------|
| Variation typeIA/ EMA/VR/0000288185 | B.III.1.aEuropeanPharmacopoeial CertificateofSuitability to therelevantPh. Eur.Monograph-B.IlI.1.a.2 Updated certificate from an already approved manufacturer-Accepted                                                                                                                                                                                                                                                                                                                                  | 28/07/2025 | N/A |      |                     |
| Variation type IB /                 | This was an application for a group of variations. B.1I.e.2Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.z Other changes-Accepted B.II.e.2Changeinthespecification parameters and/or limits of the immediate packaging of the finishedproduct-B.II.e.2.z Other changes -Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product-B.II.e.2.z Other changes-Accepted | 24/06/2025 | N/A |      | EMA/VR/0000273521   |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000252767   | B.III.1.bEuropeanPharmacopoeial TSE Certificate ofsuitabilityforan active substance/startingmaterial/reagent/ intermediate/or excipient-B.1l1.1.b.3 Updatedcertificatefrom analready approved manufacturer-Accepted   | 20/02/2025   | N/A   |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|